CLDN3 and cancer: Then, we used these monovalent format antibodies against EpCAM or CLDN3 to test their binding and internalization activity in OVCAR-3 and NCI-H1781 cancer cells, ultimately obtaining five EpCAM antibodies and three CLDN3 antibodies that met the requirements.